Possibilities of preclinical type-1 diabetes diagnostics and methods of detection of autoreactive T cells;Možnosti diagnostiky preklinického stadia diabetu 1. typu a metody průkazu autoreaktivních T lymfocytů

Diabetologie Metabolismus Endokrinologie Vyziva

Volumn 6, Issue 2, 2003, Pages 70-78

  Saudková, Ludmila ^a,b   Saudek, František ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Autoantibodies; Autoantigens; Autoreactive T lymphocytes; Cellular immunity; Humoral immunity; Type 1 DM

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL DAMAGE; CELL FUNCTION; CIRCULATION; EARLY DIAGNOSIS; FREEZING; HUMAN; HUMORAL IMMUNITY; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE COUNT; MEDICAL SOCIETY; PANCREAS ISLET BETA CELL; PATHOGENESIS; STAGING; T LYMPHOCYTE;

EID: 0038011040     PISSN: 12119326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26 (Suppl 1): 5S-20.
2. Assan R. Feutren G, Sirmai J, Laborie C, Boitard C, Vaxiau P, Du Rostu H, Rodier M, Figoni M, Vague P, Hors J, Bach JF. Plasma C-peptide levels and clinical remission in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes 1990; 39: 768-774.
3. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-29.
4. Atkinson MA, Honeyman M, Peakman M, Roep B. T-cell markers in Type I diabetes: progress, prospects and realistic expectations. Diabetologia 2000; 43(6): 819-20.
5. Bach JM, Otto N, Nepom GT, Jung G, Cohen H, Timsit J, Boitard C, van Endert PM. High affinity presentation of an autoantigenic peptide in type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease. J Autoimmun 1997;10:375-386.
6. Bárová H, Mašek Z. Genetika diabetes mellitus 1. typu. DMEV; 2(2): 57-62.
7. Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt2+ T cells. J Exp med 1987; 166(4):823-32.
8. Bennet ST. Human type 1 diabetes and the insulin gene: principles for mapping polygenes. Annu Rev Genet 1996; 30:343-70.
9. Bingley PJ, Bonifacio E, Williams AJK, Genovese S, Botazzo GF, Gale EAM. Prediction of IDDM in the general population: strategies based on combination of autoantibody markers. Diabetes 1997; 46:1701.
10. Botazzo GF, Florin-Christensen A, Doniach D. Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine defficencies. Lancet 1974; 2:1279.
11. Buzetti R, Qattrocchi CC, Nistico L. Dissecting the genetics of type-1 diabetes: relevance of familial clustering and differences in incidence. Diabetes Metab Rev 1998; 14: 111-128.
12. Carson RT, Vignali KM, Woodland DL, Vignali DA. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. Immunity 1997; 7:387-399.
13. Dilts SM, Solvason N, Lafferty KJ. The role of CD4 and CD8 T cells in the development of autoimmune diabetes. J Autoimmun 1999; 13:285-288.
14. Elliott RB, Crossley JR, Berryman CC, James AG. Partial preservation of pancreatic beta-cell function in children with diabetes. Lancet 1981:631-632.
15. Endl J, Otto H, Günther J, Dreibush B, Donie F, Stahl P, Elbracht R, Schmitz EM, Hummel M, Ziegler AG, Wank R, Schndel DJ. Identification of naturally processed. T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphpcytes of recent onset IDDM patients. J Clin Invest 1997; 99(10): 2405-2415.
16. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du Rostu H, Rodier M, Sirmai J. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicenter double-blind trial. Lancet 1986; 2:119-24.
17. Gessl A, Waldhäusel W. Increased CD69 and human leukocyte antigen-DR expression on T lymphocytes in insulin-dependent diabetes mellitus of long standing. J Clin Endocrinol Metab 1998; 83: 2204-2209.
18. Hatzgiagelaki E, Jaeger C, Petzold R, Seissler J, Scherbaum WA, Federlin K, Bretzel RG.. The combination of antibodies to GAD-65 and IA-2ic can replace the islet-cell antibody assay to identify subjects at risk of type-1 diabetes mellitus. Horm Metab Res 1999; 31:564-569.
19. Hawkes CJ, Schloot NC, Marks J, Willemen SJM, Drijfhout JW, Mayer EK, Christie MR, Roep BO. TCLs reactive to an immunodominant epitope of tyrosine phosphatase-like autoantigen IA-2 in type 1 diabetes. Diabetes 2000;49: 356-366.
20. Kimpimaki T, Kulmala P, Savola K, Vahasalo P, Reijonen H, Ilonen J, Akerblom HK, Knip M. Disease-associated autoantibodies as surrogate markers of type I diabetes in young children at increased genetic risk. Childhood diabetes in Finland Sudy group. J Clin Endocrinol Metab 2000; 91: 1126-32.
21. LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text, 2nd ed. Lippincott Williams & Wilkins: Philadelphia USA, 2000: 347-410.
22. Lewis CM, Canafax DM, Sprafka JM, Barbosa JJ. Double-blind randomized trial of nicotinamide on early onset of diabetes. Diabetes Care 1992; 15: 121-123.
23. Mathis D, Vence L, Benoist C. β-cell death during progression to diabetes. Nature 2001; 414: 792-798.
24. Nepom GT, Lippolis JD, White FM, Masewicz S, Marto JA, Herman A, Luckey CJ, Falk B, Shabanowitz J, Hunt DF, Engelhard VH, Nepom BS. Identification and modulation of naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic decarboxylase 65 (hGAD65). Proc Natl Acad Sci 2001; 98(4): 1763-1768.
25. Nepom GT, Buckner JH, Novak EJ, Reichstetter S, Reijonen H, Gebe J, Wang R, Swanson E, Kwok WW. HLA class II tetramers: tools for direct analysis of antigen-specific CD4+T cells. Arthr Rheum 2002; 46(1):5-12.
26. Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 1996;59: 1134-48.
27. Onkamo P, Vonnen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of type-1 diabetes-the analysis of the data on published incidence trends. Diabetologia 1999; 42:1395-1403.
28. Owerbach D, Gunn S, Ty G, et al. Oligonucleotide probes for HLA-DQA and DQβ genes define susceptibility to type 1 (insulin dependent) diabetes mellitus. Diabetologia 1988;31: 751-7.
29. Patterson CC, ed. Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group. Lancet 2000;355 (9207): 873-876.
30. Peakman M, Tree TI, Endl J, van Endert P, Atkinson MA, Roep BO. Characterization of GAD 65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in the detection of autoreactive T-cells in type 1 diabetes. Report of phase II of the second international Immunlogy of Diabetes Society workshop for standardization of T-cell assays in type-1 diabetes. Diabetes 2001; 50: 1749-1754.
31. Peakman M, Wen L, McNab GL, Watkins PJ, Tan KC, Vergani D. T cell clones generated from patients with type 1 diabetes using interleukin-2 proliferate to human islet antigens. Autoimmunity 1994; 17(1):31-9.
32. Peakman M, Stevens EJ, Lohman T, Narendram P, Dromey J, Alexander A, Tomlison AJ, Trucco M, Gorga JC, Chicz RM. Naturally processed and presented epitopes of the islet autoantigen IA-2 eluted from HLA-DR4. J Clin Invest 1999; 104 (10): 1449-1457.
33. Peakman M, Dayan CM. Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire? Immunology 2001, 104: 361-366.
34. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. β-cell function in new-onset type 1 diabetes and immunomodulation with heat.shock protein peptide (DiaPep277): a randomised, double blind, phase II trial. Lancet 2001; 58: 1749-53.
35. Schloot NC, Willemen SJM, Diunkerken G, de Vries RRP, Roep BO: Cloned T-cells from a recent onset IDDM diabetes patient reactive with insulin b-chain, J Autoimmunity 1998;11:169-175.
36. Schreuder G, Tilanus M, Bontrop R, Bruining GJ, Giphart MJ, van Rood JJ, de Vries RR. HLA-DQ polymorphism associated with resistence to type 1 diabetes detected with monocloal antibodies, isoelectric point differences and restriction fragment length polymorphism. J Exp Med 1986;164:938-943.
37. Silverstein J, McLaren N, Riley W, Spillar R, Radjenovic D, Johnson S.. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988; 8: 599-604.
38. Vardi P. Adjuvant administration modulates the process of beta cell autoimmunity and prevents IDDM: introduction to human trials. Diab Metab Rev. 1993;9: 317-322.
39. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, Eisenbarth GS. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial islet Autoantibody Workshop. Diabetes 1998; 47:1857-66.
40. Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitu with splenocytes from nonobese diabetic (NOD) mice. Diabetes 1986;35(8):855-60.
41. Yamagata K, Nakajima H, Tomita K, Itoh N, Miyagawa J, Hamaguchi T, Namba M, Tamura S, Kawata S, Kono N, Kuwajima M, Noguchi T, Hanafusa T, Matsuzawa Y. Dominant TCR α-chain clonotypes and interferon-γ are expressed in the pancreas of patients with recent-onset insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1996; 34:37-46.
42. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type-1 diabetes: the 2-year analysis of the german BABYDIAB study. Diabetes 1999; 48:460-468.